Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309293883> ?p ?o ?g. }
- W4309293883 endingPage "173" @default.
- W4309293883 startingPage "164" @default.
- W4309293883 abstract "ObjectivesTo evaluate a heterologous vaccination scheme in children 3-18 years old (y/o) combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines.MethodsA phase I/II open-label, adaptive, and multicenter trial evaluated the safety and immunogenicity of two doses of FINLAY-FR-2 (subsequently called SOBERANA 02) and the third heterologous dose of FINLAY-FR-1A (subsequently called SOBERANA Plus) in 350 children 3-18 y/o in Havana Cuba. Primary outcomes were safety (phase I) and safety/immunogenicity (phase II) measured by anti-RBD immunoglobulin (Ig)G enzyme-linked immunoassay (ELISA), molecular and live-virus neutralization titers, and specific T-cells response. A comparison with adult immunogenicity and predictions of efficacy were made based on immunological results.ResultsLocal pain was the unique adverse event with frequency >10%, and none was serious neither severe. Two doses of FINLAY-FR-2 elicited a humoral immune response similar to natural infection; the third dose with FINLAY-FR-1A increased the response in all children, similar to that achieved in vaccinated young adults. The geometric mean (GMT) neutralizing titer was 173.8 (95% confidence interval [CI] 131.7; 229.5) vs Alpha, 142 (95% CI 101.3; 198.9) vs Delta, 24.8 (95% CI 16.8; 36.6) vs Beta and 99.2 (95% CI 67.8; 145.4) vs Omicron.ConclusionThe heterologous scheme was safe and immunogenic in children 3-18 y/o.Trial registryhttps://rpcec.sld.cu/trials/RPCEC00000374" @default.
- W4309293883 created "2022-11-25" @default.
- W4309293883 creator A5002113141 @default.
- W4309293883 creator A5002358569 @default.
- W4309293883 creator A5002526168 @default.
- W4309293883 creator A5002829716 @default.
- W4309293883 creator A5007632655 @default.
- W4309293883 creator A5008440586 @default.
- W4309293883 creator A5008531904 @default.
- W4309293883 creator A5008725281 @default.
- W4309293883 creator A5013171934 @default.
- W4309293883 creator A5017456174 @default.
- W4309293883 creator A5018304094 @default.
- W4309293883 creator A5019196116 @default.
- W4309293883 creator A5019237555 @default.
- W4309293883 creator A5020639180 @default.
- W4309293883 creator A5020967478 @default.
- W4309293883 creator A5022149898 @default.
- W4309293883 creator A5022399596 @default.
- W4309293883 creator A5024515140 @default.
- W4309293883 creator A5024526552 @default.
- W4309293883 creator A5024603356 @default.
- W4309293883 creator A5026195581 @default.
- W4309293883 creator A5028691466 @default.
- W4309293883 creator A5030565150 @default.
- W4309293883 creator A5031452509 @default.
- W4309293883 creator A5031946852 @default.
- W4309293883 creator A5033282725 @default.
- W4309293883 creator A5034240849 @default.
- W4309293883 creator A5035156098 @default.
- W4309293883 creator A5035190810 @default.
- W4309293883 creator A5035383408 @default.
- W4309293883 creator A5037643379 @default.
- W4309293883 creator A5040850206 @default.
- W4309293883 creator A5041229418 @default.
- W4309293883 creator A5041232377 @default.
- W4309293883 creator A5042427562 @default.
- W4309293883 creator A5051663789 @default.
- W4309293883 creator A5055171829 @default.
- W4309293883 creator A5056273662 @default.
- W4309293883 creator A5056542412 @default.
- W4309293883 creator A5059031409 @default.
- W4309293883 creator A5059777480 @default.
- W4309293883 creator A5063045472 @default.
- W4309293883 creator A5064199176 @default.
- W4309293883 creator A5064336269 @default.
- W4309293883 creator A5064397704 @default.
- W4309293883 creator A5064660762 @default.
- W4309293883 creator A5065123512 @default.
- W4309293883 creator A5066491023 @default.
- W4309293883 creator A5067098752 @default.
- W4309293883 creator A5067224676 @default.
- W4309293883 creator A5069280630 @default.
- W4309293883 creator A5069714871 @default.
- W4309293883 creator A5070540296 @default.
- W4309293883 creator A5071859069 @default.
- W4309293883 creator A5077633206 @default.
- W4309293883 creator A5077850576 @default.
- W4309293883 creator A5077985945 @default.
- W4309293883 creator A5078087144 @default.
- W4309293883 creator A5079014410 @default.
- W4309293883 creator A5079380103 @default.
- W4309293883 creator A5081508532 @default.
- W4309293883 creator A5083028754 @default.
- W4309293883 creator A5084915381 @default.
- W4309293883 creator A5085503425 @default.
- W4309293883 creator A5085593472 @default.
- W4309293883 creator A5085620054 @default.
- W4309293883 creator A5085957949 @default.
- W4309293883 date "2023-01-01" @default.
- W4309293883 modified "2023-10-10" @default.
- W4309293883 title "Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children" @default.
- W4309293883 cites W2088209741 @default.
- W4309293883 cites W2143873194 @default.
- W4309293883 cites W2548066302 @default.
- W4309293883 cites W2773578465 @default.
- W4309293883 cites W2922212539 @default.
- W4309293883 cites W3081892744 @default.
- W4309293883 cites W3127941442 @default.
- W4309293883 cites W3137142873 @default.
- W4309293883 cites W3153728956 @default.
- W4309293883 cites W3157052470 @default.
- W4309293883 cites W3163459857 @default.
- W4309293883 cites W3163785571 @default.
- W4309293883 cites W3164720238 @default.
- W4309293883 cites W3165142255 @default.
- W4309293883 cites W3173690790 @default.
- W4309293883 cites W3180045826 @default.
- W4309293883 cites W3191147326 @default.
- W4309293883 cites W3197266611 @default.
- W4309293883 cites W3201008724 @default.
- W4309293883 cites W3212487860 @default.
- W4309293883 cites W4207051048 @default.
- W4309293883 cites W4225590988 @default.
- W4309293883 cites W4225612109 @default.
- W4309293883 cites W4226291717 @default.
- W4309293883 cites W4281651241 @default.
- W4309293883 cites W4292230050 @default.